Page 23 Bain Capital Healthcare

…from lab to life
Bringing innovative therapies
to patients requires more than
scientific discovery—it depends
on a robust network of partners
that support drug development
and commercialization across
the value chain.
HCIT
Axtria delivers
AI-driven cloud
software and
analytics that
help life sciences
companies
accelerate
commercialization
and improve patient
outcomes. Our
2021 investment
fuels expansion
and innovation in
advanced analytics
and AI.
CDMO
FIS develops small-
molecule APIs
and intermediates
for global
pharmaceutical
customers. Our
2023 investment
supports its
complex chemistry
expertise and
innovation across
the pharmaceutical
supply chain.
CDMO
PCI Pharma Services
provides integrated
development,
manufacturing, and
packaging solutions
that accelerate
therapies to patients
worldwide. Our 2025
investment supports
growth in biologics,
sterile fill-finish,
and high-potent
manufacturing.
CDMO
Serán provides
advanced
formulation and
manufacturing
solutions as a
leading CDMO for
pharmaceutical and
biotech clients. Our
2024 investment
accelerates
growth and
facility expansion,
reinforcing its
role as a premier
development and
manufacturing
partner.
HCIT
Suvoda offers
technology solutions
that streamline
clinical trials from
randomization and
supply management
to eConsent and
patient outcomes.
Our 2025 investment
supports its merger
with Greenphire
to create a unified
platform enhancing
trial execution and
patient engagement.
When we say we support our
companies, we really mean it
— strategic thought, access to
capital, ecosystem value —
accelerating breakthrough science.
Adam Koppel
Partner / Life Sciences
For a full list of Bain Capital healthcare investments, see page 52.
23
Bain Capital Healthcare Life Sciences